QUOTE AND NEWS
Motley Fool  8 hrs ago  Comment 
French biopharma Sanofi offers one of the highest-dividend yields in the healthcare sector. But is the stock a buy?
Reuters  Oct 2  Comment 
Sanofi's head of France, Christian Lajoux, plans to leave at the end of the year after 21 years with the drug making company, Chief Executive Chris Viehbacher said in a message to...
FierceBiotech  Oct 1  Comment 
French pharma giant Sanofi has unveiled plans to bring together the drug development work being done in a dozen different Pacific Rim countries, creating a major new R&D center in Shanghai that will employ 1,400 staffers.
Forbes  Sep 30  Comment 
On December 3 and December 4, Forbes will be hosting the third annual Forbes Healthcare Summit here in Manhattan. This invite-only event has become a big success for us --  a convergence point for big thinkers from pharmaceuticals, insurance,...
FierceBiotech  Sep 30  Comment 
Regeneron and partner Sanofi have notched another midstage milestone with their in-development allergy drug, a victory that affirms the hypothesis behind a treatment the companies believe could bring in billions.
StreetInsider.com  Sep 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Sanofi+%28SNY%29%2C+Regeneron+%28REGN%29+Report+Dupilumab+Phase+2a+Met+Primary%2C+Secondary+Endpoints/9869338.html for the full story.
SeekingAlpha  Sep 26  Comment 
By Grant Wilson: MannKind's (NASDAQ:MNKD) diabetes drug Afrezza has the potential to steal a lot of share in a growing market. Insulin user growth has outpaced the growth of those diagnosed over the past 5 years - a trend that is likely to...
Market Intelligence Center  Sep 26  Comment 
Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with Sanofi-Aventis (SNY) that should provide a 2.14% return in just 85 days. Sell one Dec. '14 call at the $55.00 level for each 100 shares of...
Reuters  Sep 25  Comment 
MannKind Corp shares were among the most actively traded in premarket on Thursday, after the company said it had closed a licensing agreement with Sanofi for the development and commercialization of its inhaled insulin product.
StreetInsider.com  Sep 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/MannKind+%28MNKD%29%2C+Sanofi+%28SNY%29+Close+Global+Development%2C+Commercialization+Agreement+for+Afrezza/9858905.html for the full story.




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki